Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson (NYSE:JNJ) revealed results from a Phase 1 study of an innovative intravesical drug-releasing mechanism with erdafitinib (Erda-iDRS) in patients with non-muscle-invasive bladder cancer who had specific fibroblast growth factor receptor mutations. Pixabay/Public Domain According to the company, the trial met its major safety goals. The intermediate-risk sample of 62 patients had an 89% co ...